Legend Biotech (LEGN)
(Real Time Quote from BATS)
$37.44 USD
-0.98 (-2.55%)
Updated Aug 6, 2025 03:46 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LEGN 37.44 -0.98(-2.55%)
Will LEGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LEGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LEGN
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?
What Makes Legend Biotech (LEGN) a New Buy Stock
LEGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet
Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?
Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains?
Other News for LEGN
Why Johnson & Johnson Stock Still Has Room To Run
Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results | LEGN Stock News
Legend Biotech Corp (LEGN) Announces Upcoming Conference Call to Discuss Q2 2025 Results | LEGN ...
Looking Into Legend Biotech's Recent Short Interest
Legend Biotech (LEGN) Receives 'Buy' Rating from HC Wainwright & Co. | LEGN Stock News